Advertisement

Clinical Drug Investigation

, Volume 12, Issue 4, pp 176–180 | Cite as

Cost Analysis of Candida Infection among Surgical Intensive Care Unit Patients

  • Debra A. Goff
  • Sondra J. Sierawski
  • Robert J. Fass
Clinical Pharmacoeconomics

Summary

The purpose of this study was to identify all hospital costs associated with surgical intensive care unit (SICU) patients who were at risk from or had documented systemic Candida infection. All patients admitted or transferred to the SICU in February 1993 were eligible. Of the 117 patients evaluated, many had recognised risk factors for systemic Candida infection, but based on eventual outcome, only 20 (17% of those admitted) were evaluated as high risk, i.e. those in the SICU ≥ 4 days on broad spectrum antibacterials with continued fever, hypothermia, or use of corticosteroids. When comparing the high risk group with a lower risk group, the increase in cost of hospital care was approximately $US41 000 per patient. Future clinical studies should evaluate if empirical antifungal agents can impact on the morbidity, mortality and economic burden incurred by Candida infection in high risk SICU patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. Am J Med 1991; 91 Suppl. 3B: 86S–9SPubMedCrossRefGoogle Scholar
  2. 2.
    Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414–21PubMedCrossRefGoogle Scholar
  3. 3.
    Beck-Sagué CM, Jarvis WR, the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. J Infect Dis 1993; 167: 1247–51PubMedCrossRefGoogle Scholar
  4. 4.
    Jarvis WR, Martone WJ. Predominant pathogens in hospital infection. J Antimicrob Chemother 1992; 29 Suppl. A: 19–24PubMedGoogle Scholar
  5. 5.
    Komshian SV, Uwaydah AK, Sobel JD, et al. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379–90PubMedCrossRefGoogle Scholar
  6. 6.
    Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642–5PubMedCrossRefGoogle Scholar
  7. 7.
    Guiot HFL, Fibbe WE, van’t Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18: 525–32PubMedCrossRefGoogle Scholar
  8. 8.
    Sobel JD. Candida infections in the intensive care unit. Crit Care Clin 1988; 4: 325–44PubMedGoogle Scholar
  9. 9.
    Edwards Jr JE. Candida species. In: Mandell GL, Douglas Jr RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 1943–58Google Scholar
  10. 10.
    Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 1598–601PubMedCrossRefGoogle Scholar
  11. 11.
    Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989; 149: 2349–53PubMedCrossRefGoogle Scholar
  12. 12.
    Eubanks PJ, de Virgilio C, Klein S, et al. Candida sepsis in surgical patients. Am J Surg 1993; 166: 617–20PubMedCrossRefGoogle Scholar
  13. 13.
    Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274(8): 639–44PubMedCrossRefGoogle Scholar
  14. 14.
    Gaines JD, Remington JS. Diagnosis of deep infection with Candida: a study of Candida precipitins. Arch Intern Med 1973; 132: 699–702PubMedCrossRefGoogle Scholar
  15. 15.
    Sugar AM. Problems in the diagnosis of invasive candidiasis in the immunocompromised patient. In: Richardson RG, editor. Opportunistic fungal infections: focus on fluconazole. International Congress and Symposium Series No. 153. London: Royal Society of Medicine Services Ltd, 1989: 17–24Google Scholar
  16. 16.
    Edwards Jr JE. Candidemia and Candida catheter-associated sepsis. In: Holmberg K, Meyer RD, editors. Diagnosis and therapy of systemic fungal infections. New York: Raven Press, 1989: 39–46Google Scholar
  17. 17.
    Fass RJ, Goff DA, Sierawski SJ. Candida infections in the surgical intensive care unit (SICU). J Antimicrobial Chemother. In pressGoogle Scholar
  18. 18.
    Dasta JF, Armstrong DK. Pharmacoeconomic impact of critically ill surgical patients. Drug Intell Clin Pharm 1988; 22: 994–8PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Debra A. Goff
    • 1
  • Sondra J. Sierawski
    • 1
  • Robert J. Fass
    • 2
  1. 1.Department of PharmacyOhio State University Medical CenterColumbusUSA
  2. 2.Department of Internal Medicine, Division of Infectious DiseaseOhio State University, College of MedicineColumbusUSA

Personalised recommendations